Clinical and Molecular Spectrum of DDX41 Variants in Korean Patients with Hematologic Malignancies
Open Access
- 11 November 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 7999
Abstract
Background: DDX41 is one of the most frequent adult-onset myeloid neoplasm predisposition gene, yet its biology remains incompletely defined. This study investigated the frequency, spectrum, and clinical characteristics of DDX41 variants in Korean patients with hematologic malignancies, including the patterns of co-occurring somatic variants. Methods: We retrospectively reviewed 716 patients with hematologic malignancies who underwent targeted next-generation sequencing. In patients with germline DDX41 variants, clinicopathologic features, co-occurring variants, variant allele frequency (VAF) distributions, and survival were analyzed. Results:DDX41 variants were identified in 34/716 patients (4.7%), including 33 germline carriers (4.6%), occurring most frequently in AML (6.2%) and MDS (11.1%). Patients with germline DDX41 variants had a median age of 68 years, were predominantly male (69.7%), and commonly had normal karyotypes (72.7%), with similar features in AML and MDS except for lower platelet counts in AML (p = 0.025). The most common germline DDX41 variants were Y259C (20.6%), A500fs (14.7%), E7* (11.8%), V152G (11.8%), and D139G (8.8%), with null variants predominating in AML and missense variants in MDS (p = 0.002). Somatic DDX41 variants occurred in 63.6% of patients with germline DDX41 variants, with R525H being the most frequent (48%), while non-DDX41 somatic variants were detected in 78.8% of patients, most commonly involving ASXL1, DNMT3A, SRSF2, and TET2, which appeared at lower VAFs, suggesting late acquisition. Conclusions: This study demonstrates ethnic-specific DDX41 variant patterns in Korean myeloid neoplasm patients, with biallelic alterations potentially involved in early leukemogenesis. These findings provide further insight into the unique features of DDX41-associated myeloid neoplasms.Keywords
Funding Information
- National Research Foundation of Korea (RS-2025-00519514)
This publication has 29 references indexed in Scilit:
- Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysisAnnals of Hematology, 2025
- Evaluation of the pathogenic potential of germline DDX41 variants in hematopoietic neoplasms using the ACMG/AMP guidelinesInternational Journal of Hematology, 2024
- Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAmerican Journal of Hematology, 2023
- A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopeniasGenetics in Medicine, 2022
- AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcomeLeukemia, 2021
- DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk diseaseAmerican Journal of Hematology, 2019
- Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterionHuman Mutation, 2018
- REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense VariantsThe American Journal of Human Genetics, 2016
- Inherited and Somatic Defects in DDX41 in Myeloid NeoplasmsCancer Cell, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015